This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

23 Dec 2015

Celgene settles Revlimid patent litigation

Natco to acquire licence to sell generic Lenalidomide in the US without volume limitation commencing in late January, 2026.

Celgene Corp. has announced the settlement of litigation with Natco Pharma Ltd of India, Natco's US partner, Arrow International Limited, and Arrow's parent company, Watson Laboratories, Inc. (a wholly-owned subsidiary of Allergan plc) relating to patents for Revlimid (lenalidomide).

As part of the settlement, the parties will file Consent Judgments with the US District Court for the District of New Jersey that enjoin Natco from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement, as described below.

In settlement of all outstanding claims in the litigation, Celgene will permit entry of generic lenalidomide before the April 2027 expiration of Celgene's last-to-expire patent listed in the Orange Book for Revlimid. Celgene has agreed to provide Natco with a licence to Celgene's patents required to manufacture and sell an unlimited quantity of generic lenalidomide in the US beginning on 31 January 2026. In addition, Natco will receive a volume-limited licence to sell generic lenalidomide in the US commencing in March 2022. The volume limit is expected to be a mid-single-digit percentage of the total lenalidomide capsules dispensed in the US during the first full year of entry. The volume limitation is expected to increase gradually each 12 months until March of 2025, and is not expected to exceed one-third of the total lenalidomide capsules dispensed in the US in the final year of the volume-limited license under this agreement. Natco's ability to market lenalidomide in the US will be contingent on its obtaining approval of an Abbreviated New Drug Application.

"We believe strongly in our patent estate for Revlimid, and that this settlement appropriately recognizes the strength of our patents. This settlement provides clarity around the future of Revlimid, and we will continue to focus on developing our many important pipeline assets, which provide great potential promise to patients with unmet medical needs," said Bob Hugin, Chairman and CEO of Celgene Corporation. "We remain confident in the strength of our patents, and will continue to vigorously defend them."

Related News